There are several targeted agents that have been approved by the Food & Drug Administration (FDA) for the treatment of renal cell carcinoma (RCC). Although targeted therapies have improved patient outcomes, they do not achieve a durable complete response. Now, immune checkpoint inhibitors are gaining FDA approvals in RCC, with additional immunotherapeutic agents being studied in RCC, including combination strategies with targeted therapy and other immunotherapies.
Clinical decision-making concerning sequencing of therapies for patients with RCC has become much more complex in the era of ever-increasing treatment options and advances in clinical trial research. Translating the most effective strategies for optimizing patient outcomes across multiple lines of therapy is becoming increasingly challenging for clinicians given the vast amount of new information. The emergence of immunotherapeutic and targeted compounds has raised many questions about how to optimize patient outcomes by the effective selection, timing, combination, and optimal sequencing of these agents.
This activity will review clinical advances and emerging research for immunotherapeutic agents and combination strategies for the treatment of advanced renal cell carcinoma, including FDA-approved immunotherapies, guideline recommendations, recent clinical trial data on immunotherapy combination strategies, and adverse event management.